Xcout Intel
Aclipse Therapeutics LLC competitors & alternatives
The 12 closest competitors and alternatives to Aclipse Therapeutics LLC among biotechnology companies — ranked by similarity to what Aclipse Therapeutics LLC actually does, not by market-cap band.
Subscribe to see Aclipse Therapeutics LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Aclipse Therapeutics LLC
Aclipse Therapeutics is a clinical-stage biopharmaceutical company that develops novel, disease-modifying drug candidates for severe and life-threatening conditions such as gastroparesis and amyotrophic lateral sclerosis (ALS). The company leverages genomic, proteomic, and biomarker data to target molecular pathways involving inflammation, cellular stress, and protein misfolding, while also implementing patient stratification approaches to improve clinical outcomes.
Aclipse Therapeutics LLC at a glance
Aclipse Therapeutics LLC is a biotechnology company headquartered in United States. It has raised at least $2.5M across the 5 funding rounds on record. Its most recent funding round raised $115,000 in August 2020. Xcout tracks 6 named people at Aclipse Therapeutics LLC, including Raymond K. Houck (CEO & President).
Aclipse Therapeutics LLC leadership
- Raymond K. HouckCEO & President
- Ira KalfusChief Medical Officer
- Michael KrandaChief Business Officer
- Ning ShanChief Scientific Officer
- Brian MoyerVice President, Corporate Development and Finance
- H. Joseph ReiserChairman of the Board
Aclipse Therapeutics LLC funding rounds
At least $2.5M raised across the 5 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $115,000 | — | |
| SEC Form D filing | $25,000 | — | |
| SEC Form D filing | $200,000 | — | |
| SEC Form D filing | $1.1M | — | |
| SEC Form D filing | $1.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Aclipse Therapeutics LLC competitors
Ranked by semantic similarity — how close each company is to Aclipse Therapeutics LLC by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.
Life Sciences
Libra Therapeutics is a biopharmaceutical company headquartered in Del Mar, California, focused on developing novel disease-modifying therapeutics. The company aims to restore cellular balance and improve lysosomal function to halt neurodegeneration in conditions such as amyotrophic lateral sclerosis.
Biotech
Vogenx, Inc. is a clinical-stage biopharmaceutical and life science company that discovers and develops novel therapeutics to treat metabolic and gastrointestinal diseases, including post-bariatric hypoglycemia and gastroparesis. Its lead drug candidate, mizagliflozin, is an oral small molecule designed to inhibit SGLT1, reducing glucose absorption and the secretion of insulin and gastric inhibitory peptide.
Similar biotechnology company
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Similar biotechnology company
BioEclipse Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in California. The company is focused on researching and developing a novel generation of targeted immunotherapies and treatments for oncology.
Similar biotechnology company
Crucible Therapeutics is a biopharmaceutical company founded in 2023 to develop novel therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, originating from research at the Sheffield Institute for Translational Neuroscience.
Biotech
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Biotech
Aptose Biosciences Inc. is a clinical-stage biotechnology company that develops small molecule cancer therapeutics, focusing on precision medicines for hematologic malignancies. The company's product pipeline features investigational drug candidates such as tuspetinib and luxeptinib, which are designed to treat conditions like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and B-cell malignancies.
Biotech
AcuraStem Inc. is a biotechnology company founded in 2016 and headquartered in Pasadena, California, focused on developing potential therapies for neurodegenerative diseases like ALS.
Biotech
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Similar biotechnology company
Accent Therapeutics, Inc. is a biopharmaceutical company headquartered in Lexington, Massachusetts, focused on translating scientific research into novel therapeutics. The company conducts clinical trials, such as Phase 1/2 studies, targeting oncology and other serious diseases.
Similar biotechnology company
Acesis Holdings Corp. is a biomedical company that develops oral, non-steroid proprietary peptide drug candidates to treat metabolic and endocrine disorders, with an initial focus on male hypogonadism and related co-morbidities. The company serves patients experiencing declining testosterone levels by providing alternatives designed to stimulate natural testosterone production.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Aclipse Therapeutics LLC and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Aclipse Therapeutics LLCand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →